Comparing Nifuroxazide Plus Lactulose With Lactulose Alone in the Treatment of Hepatic Encephalopathy
Hepatic Encephalopathy
About this trial
This is an interventional treatment trial for Hepatic Encephalopathy focused on measuring Clinical Hepatic Encephalopathy Staging Scale, Hepatic encephalopathy, Nifuroxazide
Eligibility Criteria
Inclusion Criteria: Patients suffering from liver cirrhosis aging from 18-64 years who will be admitted to hospital with neuropsychiatric condition suggestive of hepatic encephalopathy (grade II or III) confirmed by their known previous hepatic disease by history, clinical examination and laboratory investigations in the form of hyperammonemia with Model for End-Stage Liver Disease (MELD) score ≤ 25 and patients are able to swallow. Exclusion Criteria: Patients with neurological or communication problems. Degenerative central nervous system (CNS) disease. Any significant psychiatric illness. Patients with previous intake of nifuroxazide and rifaximin within the last month. Presence of underlying renal impairment (serum creatinine ≥ 2 mg/dL). Alcohol consumption within prior 4 weeks. Non-hepatic metabolic encephalopathy. Anemia with hemoglobin level < 7 g/dL.
Sites / Locations
- National Hepatology and Tropical Medicine Research Institute (NHTMRI)Recruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
lactulose plus nifuroxazide
Lactulose alone
Nifuroxazide dosing : 800 mg daily in 4 divided doses for 7 days Lactulose dosing : 30 to 60 mL PO TID to produce 2 to 3 semisoft stools per day.
Lactulose dosing : 30 to 60 mL PO TID to produce 2 to 3 semisoft stools per day.